Journal article
Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia
Abstract
On the basis of the data suggesting that adolescents and young adult patients with acute lymphoblastic leukemia (ALL) have improved outcomes when treated on pediatric protocols, we assessed the feasibility of treating adult patients aged 18–50 years with ALL with the DFCI Pediatric ALL Consortium regimen utilizing a 30-week course of pharmacokinetically dose-adjusted E. coli L-asparaginase during consolidation. Between 2002 and 2008, 92 …
Authors
DeAngelo DJ; Stevenson KE; Dahlberg SE; Silverman LB; Couban S; Supko JG; Amrein PC; Ballen KK; Seftel MD; Turner AR
Journal
Leukemia, Vol. 29, No. 3, pp. 526–534
Publisher
Springer Nature
Publication Date
March 2015
DOI
10.1038/leu.2014.229
ISSN
0887-6924
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsAsparaginaseCytarabineDoxorubicinDrug Administration ScheduleFemaleHumansKaryotypingMaleMethotrexateMiddle AgedPrecision MedicinePrecursor Cell Lymphoblastic Leukemia-LymphomaPrednisoneRemission InductionSurvival AnalysisTreatment OutcomeVincristine